Sorafenib exerts anti-glioma activity in vitro and in vivo.

  title={Sorafenib exerts anti-glioma activity in vitro and in vivo.},
  author={Markus David Siegelin and Christopher M. Raskett and Candace A. Gilbert and Alonzo H. Ross and Dario C. Altieri},
  journal={Neuroscience letters},
  volume={478 3},
Despite conventional treatment strategies glioblastoma, the most common malignant primary brain tumor, has a bad prognosis with median survival times of 12-15 months. In this study, the efficacy of sorafenib (Nexavar, BAY43-9006), a multikinase inhibitor, on glioblastoma cells was evaluated both in vitro and in vivo. Treatment of established or patient-derived glioblastoma cells with low concentrations of sorafenib caused a dramatic dose dependent inhibition of proliferation (IC(50), 1.5 microM… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 35 extracted citations

Similar Papers

Loading similar papers…